Oregon and Lantern collaborate to develop drug candidate for various cancer indications
Anticancer drugs will be responsible for 90% of nearly 612,000 predicted US cancer deaths in 2024 Oregon Therapeutics and Lantern
READ MOREMay 10, 2024
Anticancer drugs will be responsible for 90% of nearly 612,000 predicted US cancer deaths in 2024 Oregon Therapeutics and Lantern
READ MOREGossamer’s seralutinib is designed to treat pulmonary arterial hypertension and other indications Chiesi Group and Gossamer Bio have announced a
READ MOREThe findings could potentially lead to new therapies and could stop the growth of cancers Johns Hopkins Medicine scientists have
READ MOREThe rare and fatal progressive neurodegenerative disease is estimated to affect 5,000 people in the UK The Francis Crick Institute
READ MOREThe chronic brain disease that causes seizures currently affects around 600,000 people living in the UK The NHS has announced
READ MOREBladder cancer, including papillary tumours, is the ninth most common cancer type worldwide Researchers from ETH Zurich and University Hospital
READ MOREThe INTerpath-001 trial is evaluating Moderna/Merck’s mRNA-4157 in combination with Merck’s Keytruda A phase 3 international trial evaluating a new
READ MOREDespite ever increasing funding, clinical trials in primary biliary cholangitis (PBC) continue to struggle. PBC is an often silent, rare
READ MORENeurological disorders, such as epilepsy or chronic pain, affect over three billion people worldwide Researchers at the University of Cambridge
READ MOREBacteroides fragilis in the gut improves immunity and immunotherapy treatment responses Researchers from the Francis Crick Institute, the National Cancer
READ MORE